Mirobact (Mupirocin)

Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme required for protein synthesis. By blocking the attachment of isoleucine to its tRNA, the drug prevents bacterial protein formation, leading to growth arrest and bacterial cell death, especially against Staphylococcus aureus and Streptococcus pyogenes.

The prescribed dose of Mirobact is determined by the treating clinician. Typically, a thin layer is applied to the cleaned, affected skin area one to three times daily, but the exact regimen, duration and quantity should follow the prescriber’s instructions.

Safety data for mupirocin in pregnancy and lactation are limited. The product’s pregnancy category is unknown, so it should only be used when the potential benefit justifies any potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order Mirobact, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

The most common alternative to mupirocin is fusidic acid, another topical antibacterial. Both target Gram‑positive skin pathogens, but mupirocin has a broader spectrum against methicillin‑resistant Staphylococcus aureus (MRSA). Resistance patterns, local guidelines and patient tolerance often guide the choice between the two agents.

Mirobact should be stored at room temperature, below 25 °C, in its original container. Keep the tube tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children. Do not freeze or refrigerate the product.

Mirobact is applied topically. Clean and dry the affected skin area, then spread a thin, even layer of the cream or ointment over the lesion. The usual frequency is one to three times per day, as directed by a healthcare professional, and treatment continues until the infection resolves.

Serious adverse reactions, although rare, include allergic contact dermatitis, Stevens‑Johnson syndrome, anaphylaxis and systemic effects such as neutropenia from extensive absorption. Patients should discontinue use and seek immediate medical attention if they develop severe rash, blistering, fever, or signs of an allergic reaction.

Mirobact should not be used by individuals with a known hypersensitivity to mupirocin or any component of the formulation. It is also contraindicated on large body surface areas (>10 % of total skin) without medical supervision, on mucous membranes, eyes, or in patients where systemic absorption could be hazardous.